Advanced Nutriceuticals, LLC, Indianapolis, IN
Is Advanced Nutriceuticals, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Advanced Nutriceuticals, LLC hold a Indiana pharmacy license?
State board of pharmacy records for Indiana are not checked: the Professional Licensing Agency sells its license files rather than publishing them, and its discipline records are behind an interactive search.
Has Advanced Nutriceuticals, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Nov 10, 2021), 1 warning letter close-out (Feb 24, 2026), 1 state referral letter (Jul 29, 2025) and 1 FMD-145 letter (Jul 28, 2025) for Advanced Nutriceuticals, LLC. State board of pharmacy records for Indiana are not checked: the Professional Licensing Agency sells its license files rather than publishing them, and its discipline records are behind an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Advanced Nutriceuticals, LLC
- Location
- Indianapolis, IN
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Feb 24, 2026
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 25 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Advanced Nutriceuticals, LLC, a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Feb 24, 2026 | Warning letter close-out | Warning Letter Closeout Issued 02/24/2026 | fda.gov |
| Jul 29, 2025 | State referral letter | State Referral Letter Issued 7/29/2025 | Not linked by FDA |
| Jul 28, 2025 | FMD-145 letter | FMD-145 Letter Issued 07/28/2025 | Not linked by FDA |
| Nov 22, 2024 | Form 483 | 483 Issued 11/22/2024 | fda.gov |
| Nov 10, 2021 | Warning letter | Warning Letter (11/10/2021) | fda.gov |
| Oct 29, 2020 | Form 483 | 483 Issued 10/29/2020 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Advanced Nutriceuticals, LLC, Indianapolis, IN (FEI number 3010039017), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 22, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010039017 | 1256873 |
Form 483s FDA has published for this site
- Nov 22, 2024: Form 483 to Advanced Nutriceuticals, LLC, published Jun 20, 2025. fda.gov
- Oct 29, 2020: Form 483 to Advanced Nutriceuticals, LLC, published Dec 16, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 25 numbered observations in all, across 2 inspections ending Oct 29, 2020 to Nov 22, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 13, 2024 to Nov 22, 2024: 10 observations
- Firm on the cover
- Advanced Nutriceuticals, LLC, 836 E 86th St, Indianapolis, IN 46240 -1806
- FEI number
- 3010039017
- Establishment type on the cover
- Sterile and Non-Sterile Drug Producer
- FDA district office on the cover
- 300 River Place, Suite 5900 Detroit, MI 48207
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
The media fill process does not simulate aseptic processing under worst-case conditions. The technicians and pharmacist involved in sterile processing have peiformed media fills using a <Redacted B4>. This involves aseptically transferring <Redacted B4> from <Redacted B4> vial sets into a <Redacted B4> stenle vial, with <Redacted B4> vials filled with media for incubation. The current media fill simulates the preparation of a single intravenous (IV) bag; however, technicians produce up to <Redacted B4> bags <Redacted B4>, averaging ~ IV bags per day, with a maximum of <Redacted B4> IV bags in <Redacted B4> . For example, on 11/13/ 2024, 4 it was observed that technician ill prepared a total of <Redacted B4> IV bags (with a BUD) <Redacted B4> by mixing up to <Redacted B4> vials into each IV ag, with <Redacted B4> IV bags and ~ IV bags prepared <Redacted B4> in the ISO 5 Laminar Airflow Hood (LAFH).
Observation 2
The ISO 5 classified area is located within a non-classified room.
Specifically,
The ISO 5 LAFH, Equipment ID 132224, used for mixing sterile vials into IV bags for infusion, is located within an unclassified room. The most recent <Redacted B4> certification of the ISO 5 LAFH, dated 6/4/2024, did not include a classification of the IV room. Your firm has been using this IV room since 04/2021.
dated 6/4/2024, did not include a classification of the IV room. Your fnm has been using this IV room since 04/2021.
Observation 3
Vermin or other animals or evidence of their presence was observed in the areas adjacent to production areas.
Specifically,
On 11/13/2024, during the compounding of Estradiol (Lot# 11-13-2024L, 600 capsules, BUD: 5/12/2025), the following observations were made:
A. Dead Insects in Biological Safety Cabinets ~BSCs): Dead mosquitoes and other unidentified insects were observed on the isolated top layer of <Redacted B4> Biological Safety Cabinets (BSCs), Equipment IDs <Redacted B4> where exhausted air passes through. Although these insects were not in the airect proauct processmg area, their presence on the BSC exhaust layer indicates that contaminants may have ever entered the processing area, which maintains negative pressure relative to the surrounding environment and then exhausted. It remains unclear when and how these insects entered the BSCs, which are located in a segregated and enclosed suite. The fnm has been compounding hazardous drugs in this newly constructed hazardous facility since 04/2023, producing approximately <Redacted B4> batches per day.
B. Live Spider in Non-Sterile Compounding Room: A live spider was observed in the non-sterile hazardous drug compounding room. ...
Observation 4
Use of a sporicidal agent in the facility's was infrequent.
Specifically,
Your firm uses a sporicidal agent to clean the ISO 5 LAFH <Redacted B4>. For example, on 11/13/2024, after completing the mixing of <Redacted B4> IV batches, it was observed a technician cleaning the ISO 5 LAFH using a wiper wit <Redacted B4> without using a sporicidal agent.
J·
Your environmental sampling report, dated June 11, 2024, identified fungal growth in the surface sample and mold growth in the air sample within the IV room.
Observation 5
Contamination was observed in your production area and areas adjacent to production areas.
Specifically,
A. On 11/13/2024, yellow stain spots were observed inside the HEPA filter of the ISO 5 LAFH after the hood had been cleaned.
B. On 11/13/2024, a cart located next to the ISO 5 LAFH, used for supply storage, was observed to be visibly dirty after cleaning was completed. On 11/14/2024, the cart remained dirty while technician f ] prepared <Redacted B4> IV bags in the ISO 5 LAFH.
Observation 6
Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.
Specifically,
On 11/14/2024, during the mixing of <Redacted B4> IV bags intended for infusion, it was observed technicianl::t failed to disinfect supplies, including syringes and needles, placed in an unclassified area before being introduced into the ISO 5 LAFH.
introduced into the ISO 5 LAFH.
Observation 7
Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.
Specifically,
Observation 8
Use of non-sterile cleaning pads and cleaning wipes in the ISO 5 area.
Specifically,
On 11/14/2023, it was observed that technician used a wiper presatlirated with <Redacted B4> to disinfect vial~ before introducing them into the ISO LAFH. These vials were subsequently used in the preparation of <Redacted B4> IV bags. The wiper package did not bear the designation "sterile", and Your firm was unable to provide documentation to verify its sterility. Additionally, your firm could not provide documentation to verify the sterility of the mop wipers used by the technician to clean the ISO 5 LAFH after completing the mixing of these IV bags.
e~q
Observation 9
Production areas have difficult to clean or contain porous, particle generating, or visibly duty equipment or surfaces.
Specifically,
A. On 11/14/2024, it was observed technician <Redacted B4> did not conduct thorough cleaning, particularly on the grill of the HEP A filter. the interior surfaces of the front shield, devices installed inside the ISO 5 LAFH, such as the <Redacted B4> and outlet, after IV bag mixing was completed.
B. Unknown powders were observed on the wheels of the balance and along the edge of the BSC hood after the compounding of Estradiol (Lot# ll-13-2024L, 600 capsules, BUD: 5/12/2025) and the completion of hood cleaning.
Observation 10
Materials were exposed to lower than ISO 5 quality air.
Specifically,
On 11/13/2024 and 11/14/2024, sterile wipes were observed left open in an unclassified area on a cart near the ISO 5 LAFH. Pharmacist stated that these wipes would be used to clean the ISO 5 LAFH if mop wipers were unavailable.
Inspection Oct 13, 2020 to Oct 29, 2020: 15 observations
- Firm on the cover
- Advanced Nutriceuticals, LLC, 836 E 86th St, Indianapolis, IN 46240-1806
- FEI number
- 3010039017
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- 300 River Place, Suite 5900 Detroit, MI 48207
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You performed aseptic processing outside of a certified ISO 5 area.
Specifically,
On 10/20/2020 we observed your dispensary staff with exposed hands, hair, and streetwear fill <Redacted B4> lML syringes using a stock solution containing Testosterone Cypionate w/ Olive Oil, LOT <Redacted B4> (EXP 11/30/2020) 10 ML vial inside the unclassified Dispensaiy Area. In addition, an expiry of 11/30/2020 (BUD 40 days) is assigned to these filled syringes. Any employee in the Dispensaiy Area can fill these stock solutions into syringes without completing any documentation or receiving training.
• From 08/03/2020 to 09/25/2020, dispensary staff filled and dispensed approximately <Redacted B4> batches of syringes of syringes of Testosterone Cypionate w/ Olive Oil in the Dispensary Area. The expily dates for the stock solutions were assigned to these filled syringes. Each batch contained between <Redacted B4> syringes.
• From 08/03/2020 to 09/25/2020 dispensary staff filled and dispense approximately <Redacted B4> batches of syringes of Nandrolone wl Olive Oil in the Dispensary Area. The expiry dates or the stock solutions were assigned to these filled syringes. ...
Observation 2
The ISO 5 classified aseptic processing area was located within a non-classified room (segregated production area).
Specifically,
The ISO 5 IV hood used to produce IV bags is located within the unclassified IV room. This room is an office for your Naturopathy doctor and Phlebotomist <Redacted B4>. There are computers, printers, and two doors leading into this room where the ISO 5 IV hood is located. Your IV room is unclassified. For example, your patient records show that on 09/30/2020 your Naturopathy doctor produced an IV bag using <Redacted B4>. According to your Naturopathy doctor, this IV bag with <Redacted B4> additive was produced inside the ISO 5 IV hood in the IV room. An expiration date of "03-Oct-2020" was assigned to this IV bag according to your patient IV therapy records. This IV bag was shipped from your clinic to a patient located in California on 09/30/2020 and arrived on 10/01/2020.
Observation 3
Your employees touched equipment and other surface areas outside the ISO 5 area with gloved hands and proceeded to aseptically process drug product without changing or sanitizing gloves.
Specifically,
On 10/14/2020 and 10/16/2020, we observed your sterile technician perform aseptic techniques in the ISO 5 Cleanroom hood. Your sterile technician 's practice of sanitizing sterile gloved hands and changing of gloves in between contacting non-sterile and sterile materials is inadequate. For example:
A) On 10/16/2020 while aseptically processing Selank 1000MCG/ML 5 ML, LOT 1016202002 EXP 11/1 6/2020 from non-sterile to sterile in the ISO 5 Cleanroom hood:
1. We observed your sterile technician touch or retrieve items outside the ISO 5 Cleanroom hood a total of fourteen (14) times. These include touching the staging cart handle bar, retrieving vials from a non-sterile <Redacted B4> bag outside the ISO 5 area, and retrieving a syringe outside the ISO 5 area. In between retrieving items from outside of the ISO 5 area, we observed your employee sanitize their gloved hands only once.
2. ...
Observation 4
Your sterile technician moved rapidly in the vicinity of open sterile units or instruments.
Specifically,
On 10/16/2020 we observed your sterile technician open a <Redacted B4> packaging, attach <Redacted B4> to the syringe, and fill a vial while aseptically processing Selank 1000 MCG/ML 5 ML, LOT 1016202002 EXP 11/16/2020 from non-sterile to sterile. Your technican's movements were not slow and deliberate in this sequence of events, which occurred over the course of approximately 25 seconds.
You produced sterile drug products using non-sterile <Redacted B4> in the ISO 5 Cleanroom Hood. These products include but are not limited to: LL-37 2000MCGIML, Thymosin Beta 2000MCGIML, Thymosin Alpha 2000MCGIML, GHRP 2000MCGIML, Semax 1 000MCGIML, Selank 1 000MCGIML, Ipamorelin 2000MCGIML, BPC-157 2000 MCGIML, and Testosterone Cypionate w/ Olive Oil 200MGIML 10ML.
Observation 5
Your sterile technician conducted aseptic manipulation and placed equipment/supplies in an area that blocks the movement of first pass air around an open unit.
Specifically,
On 10/16/2020 we observed your sterile technician obstruct the first pass air around the <Redacted B4> at least eight times while aseptically processing Selank 1000 MCG/ML 5 ML, LOT 1016202002 EXP 11/16/2020 from non-sterile <Redacted B4> in the ISO 5 Cleanroom hood.
You produced sterile drug products using non-sterile <Redacted B4> in the ISO 5 Cleanroom Hood through this same <Redacted B4> stoppering process. These products include but are not limited to: LL-3 7 2000MCGIML, Thymosin Beta 2000MCGIML, Thymosin Alpha 2000MCGIML, GHRP 2000MCGIML, Semax 1 000MCGIML, Selank 1 000MCGIML, Ipamorelin 2000MCGIML, BPC-157 2000 MCGIML, and Testosterone Cypionate w/ Olive Oil 200MGIML J0ML.
157 2000 MCGIML, and Testosterone Cypionate w/ Olive Oil 200MGIML J0ML.
Observation 6
Your sterile technician stoppered sterile drug vials.
---- Specifically,
On 10/16/2020 after aseptic <Redacted B4> with a <Redacted B4> we observed your sterile technician <Redacted B4> stoppered <Redacted B4> vials containing Selank 1000 MCG/ML 5 ML vials, LOT 1016202002 EXP 11/16/2020 in the ISO 5 Cleanroom hood. After <Redacted B4> stoppering, these vials were taken into the Anteroom for crimping and labeling. You did not perform any further sterilization after the drug products were aseptically <Redacted B4> in the ISO 5 Cleanroom hood.
You produced sterile drug products using non-sterile <Redacted B4> in the ISO 5 Cleanroom Hood. These products include but are not limited to: LL-37 2000MCGIML, Thymosin Beta 2000MCGIML, Thymosin Alpha 2000MCGIML, GHRP 2000MCGIML, Semax 1 000MCGIML, Selank 1 000MCGIML, Ipamorelin 2000MCGIML, BPC-157 2000 MCGIML, and Testosterone Cypionate w/ Olive Oil 200MGIML 1 0ML.
Observation 7
Supplies outside of the ISO 5 Cleanroom hood were not disinfected prior to entering the aseptic processing areas.
Specifically,
On 10/14/2020 we observed a bottle of sterile fall onto the floor of the Cleanroom during aseptic processing of IV bags in the ISO 5 Cleanroom hood. The nozzle came into contact with the ISO 7 Cleanroom floor. Your employee proceeded to pick up the bottle from the ground and use this spray bottle in the ISO 5 area without sanitizing the nozzle.
contact with the ISO 7 Cleamoom floor. Your employee proceeded to pick up the bottle from the ground and use this spray bottle in the ISO 5 area without sanitizing the nozzle.
You produced sterile drug products using non-sterile <Redacted B4> in the ISO 5 Cleanroom Hood. These products include but are not limited to: LL-37 2000MCGIML, Thymosin Beta 2000MCGIML, Thymosin Alpha 2000MCGIML, GHRP 2000MCGIML, Semax 1 000MCGIML, Selank J000MCGIML, Ipamorelin 2000MCGIML, BPC-157 2000MCGIML, and Testosterone Cypionate w/ Olive Oil 200MGIML 1 0ML. In addition, you produced Myer's Basic IV bags through admixing with sterile ingredients made onsite from bulk to sterile in the ISO 5 Cleanroom hood. ...
Observation 8
Systems for monitoring processing and environmental conditions in aseptic processing areas were deficient.
Specifically,
A) Your employees who produced sterile drug products have never performed media fills. For example:
Your sterile technician who has been producing sterile drug products (from non-sterile to sterile and sterile-to-sterile) for over three years has never performed a media fill during this time.
Your <Redacted B4> phlebotomists and Naturopathic Doctor produce IV bags in the IV room, for shipping to out-of-state patients. They have never performed a media fill.
• Your Dispensary staff <Redacted B4> and Pharmacist fill sterile drug products in the Dispensary room. They have never performed a media fill.
B) Environmental monitoring in the aseptic processing area has not been performed since October 2018. The last time your vendor performed active air sampling in the ISO 5 Cleanroom hood and ISO 5 IV hood was on 10/26/2018. Fungal contamination (1 CFU) was detected in the ISO 5 Cleanroom hood during this sampling. Since then, you have not implemented a program to routinely monitor environmental conditions in the aseptic processing area. ...
Observation 9
Your firm exposed stock solutions, used in the production of drug products intended to be sterile, to worse than ISO 5 quality air.
Specifically,
Stock solutions were stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period. For example,
Your sterile compounding log shows that on 09/28/2020, a batch of Testosterone Cypionate w/ Olive Oil stock solution was produced using <Redacted B4> in the ISO 5 Cleanroom hood and was assigned LOT <Redacted B4> EXP 11/30/2020.
On 10/20/2020, we observed filling of syringes using of this stock solution LOT <Redacted B4> EXP 11/30/2020 stored in the unclassified Dispensary room. Prior to filling, we counted at least five (5) existing puncture marks on the vial stopper. The product had been stored at room temperature in an unclassified area for an undocumented period. ...
Observation 10
The use of sporicidal agents in the aseptic processing area were inadequate.
Specifically,
your sterile technician did not sanitize the aseptic processing area with disinfectant after maintenance to replace ceiling lights was performed in the ISO 7 Cleanroom on 10/17/2020. Your sterile technician stated that during the morning cleaning on 10/19/2020 the ceiling in the ISO 7 Cleanroom was wiped with sterile <Redacted B4> only and that disinfectant was not used until the end of the day, after several sterile drug products were made on 10/19/2020.
The following sterile drug products were made on 10/19/2020 through through non-sterile -in the ISO 5 Cleanroom hood: Bl 2 for IV 2MGIML, LOT 10192001 EXP 12/03/2020,· B Complex, LOT 1019202002 EXP 12/03/2020; Potassium Phosphate 3MMOLIML, LOT 1019202003 EXP 12/03/2020,· and Hydrogen Peroxide 3%, LOT 1019202004 EXP I 1/03/2020.
Observation 11
The final containers/closures used for drug product intended to be sterile were not sterilized or <Redacted B4>
A) <Redacted B4> vials were not appropriately handled and stored to ensure sterility at time of use, specifically, <Redacted B4> bags are reused for storing sterile vials after the vials are <Redacted B4>. For example, your vials are purchased non-sterile and <Redacted B4>. Your sterile technician stated they wrap vials with <Redacted B4> before placing it into the <Redacted B4> and after completing a <Redacted B4> cycle. It is taken into the ISO 5 Cleanroom hood to be aseptically packed into non-sterile <Redacted B4> bags. According to your sterile technician, the vials are wiped down with sterile <Redacted B4> and sterile wipes inside the ISO 5 hood before storing in a <Redacted B4> bag. When asked if the <Redacted B4> bags are ever reused for storing <Redacted B4 vials your sterile technician stated yes In addition, unused vials were stored in a non-sterile <Redacted B4> bag and reused in subsequent batches without further sterilization. ...
Observation 12
Your employee produced a sterile drug product using expired material Specifically,
On 10/16/2020, your Phlebotomist <Redacted B4> prepare and administer an IV bag containing Taurine, LOT 0827202007 in the ISO 5 IV hood. The Taurine stock solution used to make this lot had expired on 10/12/2020 (four days expired). Your patient records show that this product was administered to a patient on 10/16/2020 at 9:30AM.
Your phlebotomists produced IV bags with additives (e.g., Taurine, <Redacted B4> in the ISO 5 IV hood. These IV bag additives are shipped overnight per patient request.
Observation 13
The ISO-classified aseptic processing areas and surrounding areas had difficult to clean and visibly dirty equipment or surfaces.
Specifically,
During aseptic processing on 10/14/2020 and 10/16/2020, we observed your sterile technician produce Myer 's Basic IV Bag (from sterile-to-sterile) and Selank l000MCG/ML 5 ML, LOT 1016202002 EXP 11/16/2020 (from non-sterile <Redacted B4>) in the ISO 5 Cleanroom hood. We observed the following:
A) Rust-colored discoloration and damage on all the HEPA filters in the ISO 7 Cleamoom and ISO 8 Anteroom.
B) Rust-colored discoloration on the ISO 5 Cleanroom HEPA filter.
C) ISO 5 Cleanroom workbench is composed of wood-like laminated materials and the top of the workbench is peeling from the side that directly contacts the HEP A filter.
D) A heating vent is located directly underneath the ISO 5 Cleanroom hood and within the ISO 7 Cleanroom. On 10/22/2020, we observed filth build-ups underneath the vent screen and the vent was blowing warm air into the Cleanroom. This air supply vent does not appear to have HEPA filtered air. ...
Observation 14
Your facility design allowed the influx of poor-quality air into a higher classified area.
Specifically,
A) ISO 5 IV hood used to produce IV bags is not certified. This hood has not been certified since 10/26/2018 (for over two years). For example, your patient records show that on 09/30/2020 your Naturopathy doctor produced an IV bag using <Redacted B4> vial. According to your Naturopathy doctor, this IV bag with <Redacted B4> additive was produced inside the ISO 5 IV hood in the IV room. An expiration date of "03-Oct-2020" was assigned to this IV bag according to your patient IV therapy records. This IV bag was shipped from your clinic to a patient located in California on 09/30/2020 and arrived on 10/01/2020.
B) You do not have any room pressure monitors installed in the ISO 7 Cleanroom and the ISO 8 anteroom to monitor for potential influx of lower quality air into higher classified areas. ...
Observation 15
Beta-lactam and hazardous drugs were produced without providing adequate containment, segregation, and cleaning of work surfaces, utensils, and personnel to prevent cross-contamination.
Specifically. You produces hazardous drugs in the unclassified Dispensary Area without an adequate segregation and cleaning of equipment and work surface to prevent cross-contamination. The following table includes a list of non-sterile drug products that are produced and sterile drug products that are filled in the unclassified Dispensary Area.
I DRUG CLASS
I NON-STERILE DRUGS
I STERILE DRUGS
I I Beta-lactam
Ceftriaxone
None
I
Hazardous drugs
Anastrozole, Testosterone, Estradiol, Progesterone, Finasteride, Fluconazole, Oxytocin
Testosterone, Nandrolone
For example:
A) On 10/26/2020, we observed your non-sterile technician produce Anastrozole LOT 10-26-2020 B outside of a <Redacted B4> hood, specifically, your technician was pouring this <Redacted B4> on a counter near the sink in the unclassified Dispensary room.
B) On 10/22/2020 and 10/26/2020 we observed built-up powder residues on the inside and outside of the capsule counter machine. ...
State board of pharmacy records
State board of pharmacy records for Indiana are not checked: the Professional Licensing Agency sells its license files rather than publishing them, and its discipline records are behind an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.